|
|
||||||||
Institut für Chemie 1 (Nuklearchemie) der KFA Jülich GmbH, D-5170 Jülich, FRG
Klinik för Nuklearmedizin, D-5600 Wuppertal, FRG
Correspondence: For reprints contact: G. Stücklin, Institut för Chemie, der Kernforschungsanlage Julich GmbH, D-5170 Julich, FRG.
ABSTRACT
L-3-iodo-\ga-methyltyrosine, labeled with either I-131 or I-123, has a high pancreatic specificity in mice. A pancreas-to-liver ratio of 8.6 \+- 2.7 is observed during the first hour after i.v. injection. Accumulation is also prominent in the kidneys, but excretion of the radioagent is rapid, 50% of the activity being eliminated during 90 min. Compared with L-[75Se]selenomethionine, the compound currently used for pancreatic imaging, L-3-[123I] or [131I]iodo-\ga-methyltyrosine has a higher pancreas-to-liver ratio, a shorter physical half-life and biological half-time, and better decay characteristics.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |